巴西接种Ad26.COV2·S疫苗后抗PF4抗体阳性与血小板活化情况
在巴西里约热内卢开展的研究纳入630名Ad26.COV2·S疫苗接种者,于接种前、接种后1周和3周评估。接种后3周9人(1.57%)抗PF4抗体阳性,31人(4.91%)D-二聚体升高,5人(0.79%)血小板减少,未见临床相关的血栓炎症标志物及血小板活化增加。
要点
- 630名接种者中42人(6.67%)在接种后1周或3周出现至少1项实验室异常。
- 接种后3周抗PF4抗体阳性9人(1.57%),均为低滴度,D-二聚体升高31人(4.91%),血小板减少5人(0.79%)。
- 有实验室异常者与38名匹配对照相比,血浆p-选择素和组织因子仅轻度升高,未伴临床相关的血小板活化增加。
核心结论
- 接种Ad26.COV2·S疫苗后抗PF4低滴度抗体阳性、D-二聚体升高和轻度血小板减少的发生频率很低,未伴随临床相关的血栓炎症标志物及血小板活化增加。
研究设计与样本
- 2021年7月至9月在巴西里约热内卢开展的研究,纳入630名Ad26.COV2·S疫苗接种者,于接种前、接种后1周和3周进行评估。
- 每次访视检测血小板计数和D-二聚体,第3周检测抗PF4抗体;抗PF4阳性者回顾性检测第0周样本。
- 出现新发血小板减少或D-二聚体升高、抗PF4阳性者,与38名无实验室异常的匹配对照一起评估血浆p-选择素、组织因子及血小板功能活化试验。
主要发现
- 630名受试者中女性306人(48.57%),中位年龄28岁。
- 42人(6.67%)在接种后1周或3周出现至少1项实验室异常。
- 接种后3周血小板减少5人(0.79%),D-二聚体升高31人(4.91%),抗PF4抗体阳性9人(1.57%)。
- 有实验室异常者与对照相比血浆p-选择素和组织因子仅轻度升高。
- 10名有实验室异常者表面p-选择素表达增加,其中2人可被高浓度肝素及IV.3抗体阻断FcγRII部分抑制,但接种前血浆也产生类似结果,提示与接种无关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Ad26.COV2·S (Janssen/Johnson & Johnson) COVID-19 vaccine, has been rarely associated with vaccine-induced immune thrombocytopenia and thrombosis (VITT). We investigated the prevalence of anti-PF4 antibody positivity, thrombocytopenia, D-dimer elevation, plasmatic thromboinflammatory markers, and platelet functional assays following Ad26.COV2·S vaccination in Rio de Janeiro, Brazil. METHODS: From July to September 2021, participants were assessed prior, 1, and 3 weeks post-vaccination. Platelet count and D-dimer were measured at each visit and anti-PF4 at week 3. A positive anti-PF4 prompted retrospective testing of the sample from week 0. Individuals with new thrombocytopenia or elevated D-dimer, positive anti-PF4, and 38 matched controls without laboratory abnormalities were evaluated for plasmatic p-selectin, tissue factor, and functional platelet activation assays. RESULTS: 630 individuals were included; 306 (48.57%) females, median age 28 years. Forty-two (6.67%) presented ≥1 laboratory abnormality in week 1 or 3. Five (0.79%) had thrombocytopenia, 31 (4.91%) elevated D-dimer, and 9 (1.57%) had positive anti-PF4 at week 3. Individuals with laboratory abnormalities and controls showed a slight increase in plasmatic p-selectin and tissue factor. Ten individuals with laboratory abnormalities yielded increased surface expression of p-selectin, and their ability to activate platelets in a FcγRIIa dependent manner was further evaluated. Two were partially inhibited by high concentrations of heparin and blockage of FcγRII with IV.3 antibody. Plasma obtained before vaccination produced similar results, suggesting a lack of association with vaccination. CONCLUSIONS: Vaccination with Ad26.COV2·S vaccine led to a very low frequency of low-titer positive anti-PF4 antibodies, elevation of D-dimer, and mild thrombocytopenia, with no associated clinically relevant increase in thromboinflammatory markers and platelet activation.
引用
- Bokel J, Martins-Gonçalves R, Grinsztejn E, et al. Anti-PF4 positivity and platelet activation after Ad26.COV2·S vaccination in Brazil. Vaccine. 2024. PMID: 39107160. doi:10.1016/j.vaccine.2024.126175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。